These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
188 related articles for article (PubMed ID: 33575481)
1. Can Anti-β-amyloid Monoclonal Antibodies Work in Autosomal Dominant Alzheimer Disease? Imbimbo BP; Lucca U; Watling M Neurol Genet; 2021 Feb; 7(1):e535. PubMed ID: 33575481 [TBL] [Abstract][Full Text] [Related]
2. The potential of solanezumab and gantenerumab to prevent Alzheimer's disease in people with inherited mutations that cause its early onset. Panza F; Seripa D; Lozupone M; Solfrizzi V; Imbimbo BP; Barulli MR; Tortelli R; Capozzo R; Bisceglia P; Dimitri A; Stallone R; Dibello V; Quaranta N; Daniele A; Bellomo A; Greco A; Logroscino G Expert Opin Biol Ther; 2018 Jan; 18(1):25-35. PubMed ID: 29037101 [TBL] [Abstract][Full Text] [Related]
3. Amyloid-Related Imaging Abnormalities in the DIAN-TU-001 Trial of Gantenerumab and Solanezumab: Lessons from a Trial in Dominantly Inherited Alzheimer Disease. Joseph-Mathurin N; Llibre-Guerra JJ; Li Y; McCullough AA; Hofmann C; Wojtowicz J; Park E; Wang G; Preboske GM; Wang Q; Gordon BA; Chen CD; Flores S; Aggarwal NT; Berman SB; Bird TD; Black SE; Borowski B; Brooks WS; Chhatwal JP; Clarnette R; Cruchaga C; Fagan AM; Farlow M; Fox NC; Gauthier S; Hassenstab J; Hobbs DA; Holdridge KC; Honig LS; Hornbeck RC; Hsiung GR; Jack CR; Jimenez-Velazquez IZ; Jucker M; Klein G; Levin J; Mancini M; Masellis M; McKay NS; Mummery CJ; Ringman JM; Shimada H; Snider BJ; Suzuki K; Wallon D; Xiong C; Yaari R; McDade E; Perrin RJ; Bateman RJ; Salloway SP; Benzinger TLS; Clifford DB; Ann Neurol; 2022 Nov; 92(5):729-744. PubMed ID: 36151869 [TBL] [Abstract][Full Text] [Related]
4. Evaluation of dose-dependent treatment effects after mid-trial dose escalation in biomarker, clinical, and cognitive outcomes for gantenerumab or solanezumab in dominantly inherited Alzheimer's disease. Wang G; Li Y; Xiong C; McDade E; Clifford DB; Mills SL; Santacruz AM; Aschenbrenner AJ; Hassenstab J; Benzinger TLS; Gordon BA; Fagan AM; Coalier KA; Libre-Guerra JJ; McCullough A; Joseph-Mathurin N; Chen CD; Mummery C; Wendelberger BA; Gauthier S; Masellis M; Holdridge KC; Yaari R; Chatterjee S; Sims J; Delmar P; Kerchner GA; Bittner T; Hofmann C; Bateman RJ; Alzheimers Dement (Amst); 2022; 14(1):e12367. PubMed ID: 36348972 [TBL] [Abstract][Full Text] [Related]
5. Amyloid-directed monoclonal antibodies for the treatment of Alzheimer's disease: the point of no return? Panza F; Solfrizzi V; Imbimbo BP; Logroscino G Expert Opin Biol Ther; 2014 Oct; 14(10):1465-76. PubMed ID: 24981190 [TBL] [Abstract][Full Text] [Related]
6. Lessons Learnt from the Second Generation of Anti-Amyloid Monoclonal Antibodies Clinical Trials. Tian Hui Kwan A; Arfaie S; Therriault J; Rosa-Neto P; Gauthier S Dement Geriatr Cogn Disord; 2020; 49(4):334-348. PubMed ID: 33321511 [TBL] [Abstract][Full Text] [Related]